The medical technologies, biotechnology and pharmaceutical (MTP) sector in Australia has all the hallmarks of the high-skilled and innovation-based economy, that Australia continues to develop to secure sustainable wealth and employment growth for the future.
Australia is an acknowledged world leader in the MTP sector due to its vibrant research environment. However, its poor record of local commercialisation and tendency to see research drained offshore for development are also well known.
MTPConnect is committed to assisting Australian companies overcome the barriers that limit growth of the sector, including:
- Funding constraints and misalignment with commercial objectives
- Lack of collaboration across the sector’s various sub-segments, e.g. between industry and Universities
- Lack of commercialisation and business-management skills in specific areas of the value chain, including a deficient understanding of the pathway from research to market
- Lack of knowledge and skills for pitching to potential investors Policy instability in the areas of government program funding, intellectual property (IP) and reimbursement
- Regulatory requirements that are not aligned to innovation cycles or to supporting small to medium-sized (SMEs) businesses
- The complexity and difficulty of accessing global markets
MTPConnect’s vision is for Australia to retain all current and planned levels of research and development (R&D) investment while achieving greater commercialisation success, creating more products that reach proof-of-concept and early-stage commercialisation; increasing the number of medium-sized-to-large (SMEs) companies with late-stage product successes, and maximising the value of any IP-monetisation events along the way. MTPConnect has identified seven Sector Growth Priorities that underpin this vision, each addressing specific elements of the MTP value chain. Full details can be found in our Sector Competitiveness Plan.
Australian company Nanosonics developed the proprietary trophon® EPR for fast, automated high level disinfection (HLD) of ultrasound probes.
Amgen Australia conducts on average two ‘first in human’ studies every year, with almost half of their clinical trial research being early phase.
Monash University Faculty of Medicine, Nursing and Health Sciences was the first Australian academic research institute to be invited by Pfizer to join their Centers for Therapeutic Innovation
A collaboration between the CSIRO and Australian dental company Oventus has developed a game changing solution for people suffering from sleep apnoea.
31 Aug 2016 / News
Ms Sue MacLeman, Managing Director and CEO of MTPConnect, will present on Australia's medtech capabilities and competitive advantages at a medtech showcase in Seoul.
Ms Sue MacLeman, Managing Director and CEO MTPConnect will present on Australia's medtech capabilities and competitive advantages at a medtech Showcase in Seoul.